Dr. Chauhan on Future Directions With Lutathera in GEP-NETs

Aman Chauhan, MD, a medical oncologist at the University of Kentucky, discusses future directions with Lutathera (lutetium 177-dotatate) in gastroenteropancreatic neuroendocrine tumors (GEP-NETs).

Currently, Lutathera is a standard of care for the treatment of patients with progressive, metastatic GEP-NETs, explains Chauhan. The majority of patients respond well to Lutathera, and the median progression-free survival (PFS) is in the range of 30 to 55 months. 

However, 15% to 20% of patients with GEP-NETs do not respond to Lutathera or have inadequate responses. These patients may include those with disease in the peritoneum and those who progress rapidly following treatment with Lutathera. As such, improving Lutathera to extend the median PFS is an area of need in this space, concludes Chauhan.